Astex Pharmaceuticals, Inc.
4140 Dublin Boulevard
About Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
• Fiscal strength with significant cash, ongoing revenues and potential milestone payments
• Productive partnerships with top-tier pharmaceutical companies
• Rich product portfolio with multiple drugs in clinical development
• Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.
277 articles with Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals. Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance
Astex Pharmaceuticals Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals
Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors
Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients
Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration
Astex Pharmaceuticals President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
Astex Pharmaceuticals Release: DACOGEN® Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia